ChromaDex, Inc. on 2 November reported net sales off 1% to $17.1m, including $14.6m revenues from its Tru Niagen nicotinamide riboside supplement, but trimmed its net loss to less than $1m in its latest quarter.
US Q3 Health And Wellness Results: Chromadex, Lannett, Mannatech And USANA
ChromaDex trims loss, adds Nestle as Niagen customer; currency exchange slams Mannatech; Asia-Pacific sales, currency exchange Rock USANA results; and Lannett sees upsides after 25% sales slide.